Crossmark

Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancer

Crossref DOI link: https://doi.org/10.1007/s00404-025-07991-y

Published Online: 2025-03-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chinczewski, Lukas https://orcid.org/0000-0002-6148-5887
Harter, Philipp

Heukamp, Lukas

Mayr, Doris

Grimm, Christoph

Heinzelmann-Schwarz, Viola

Wimberger, Pauline

Mahner, Sven

Braicu, Ioana Elena

Schmitt, Wolfgang

Denkert, Carsten

Sehouli, Jalid
Funding

Funding for this research was provided by:

Charité - Universitätsmedizin Berlin
License Information

Text and Data Mining valid from 2025-03-12

Version of Record valid from 2025-03-12
More Information

Article History

Received: 30 January 2025

Accepted: 21 February 2025

First Online: 12 March 2025

Declarations

:

: AdBoard Honorary by Myriad MyChoice Honorary by GSK, ESAI and NOGGO e.V.

Document is current

Any future updates will be listed below